The Imegen BCR-ABL test is a powerful diagnostic tool for leukemia, using real-time PCR to identify BCR-ABL1 rearrangements such as M-BCR-ABL1 and m-BCR-ABL1. Leveraging complementary DNA (cDNA) samples derived from total RNA in blood cells or bone marrow, this BCR-ABL test provides essential insights into potential genetic changes.
While the test provides qualitative analysis of these gene rearrangements, it doesn’t distinguish between major and minor translocations. To ensure accurate results, Health in Code recommends adhering to local guidelines for cDNA sample preparation and assay setup. The insights gained from the test are instrumental in guiding leukemia diagnosis, making it a crucial asset for healthcare professionals.
Understanding the Imegen BCR-ABL Test
The Imegen BCR-ABL test is a breakthrough diagnostic tool designed to identify common variants of BCR-ABL1 rearrangements. Using advanced real-time PCR technology, this test plays a critical role in diagnosing various types of leukemia. By leveraging the power of molecular biology, it offers a reliable means to determine the presence of common gene rearrangements such as M-BCR-ABL1 and m-BCR-ABL1.
The Process of the BCR-ABL Test
The Imegen BCR-ABL test requires samples of complementary DNA, also known as cDNA. These samples are prepared from total RNA extracted from peripheral blood cells or bone marrow. After extraction, the RNA is reverse transcribed to form cDNA, which is then used in the test. The BCR-ABL test applies real-time PCR technology to these cDNA samples in a process known as a multiplexed reaction. During this process, the most common variants of the BCR-ABL1 rearrangement, M-BCR-ABL1, and m-BCR-ABL1 are amplified and identified.
Interpreting BCR-ABL Test Results
One of the unique characteristics of the BCR-ABL test is its qualitative analysis approach. Unlike some tests that quantify genetic material, the BCR-ABL test does not differentiate between major and minor translocations. Instead, it provides a general indication of BCR-ABL translocations, offering a valuable snapshot of these significant gene rearrangements.
Assisting Leukemia Diagnosis
The test is more than just a tool for detecting common variants of the BCR-ABL1 rearrangement. Its results provide essential guidance for clinicians in the diagnosis of leukemia types, making it an invaluable tool in the field of molecular biology and healthcare. The test is designed for in vitro diagnostics, and its results can help clinicians determine the best course of treatment for patients with leukemia.
The test stands as a significant development in the field of leukemia diagnosis. It utilizes real-time PCR to identify common variants of the BCR-ABL1 rearrangement and provides a qualitative analysis that does not distinguish between major and minor translocations. Despite this, it offers invaluable insights for clinicians in diagnosing various types of leukemia. For the most accurate results, it’s essential to follow local guidelines on sample preparation and assay setup. The test is a powerful tool for professionals in the field of molecular biology and healthcare, providing essential guidance in diagnosing leukemia.
The kit contains the following reagents required to perform 48 real-time PCR reactions for each of the two targets analyzed in this assay: